The new Advanced Proton Solutions Holdings (APS) facility that will be built in the city of London is set to install ProTom International's Radiance 330 proton therapy system.

Proton beam therapy can deliver a precise and direct dose of radiation to the solid tumors thus minimizing damage to surrounding healthy tissue and reducing side effects.

ProTom CEO Stephen Spotts said their Radiance 330 system is a great solution for sustainable urban locations such as the city of London.

APS CEO Simon Grinstead said Proton beam therapy represents an innovation in cancer treatment, and ProTom’s technology will allow the development of the APS purpose-built facility in Moorgate, City of London.